57 patientgrupper kan have forhøjet risiko for at udvikle malignt neuroleptikasyndrom samt kan have øget sensitivitet for antipsykotika; disse patienter var udelukket fra kliniske forsøg.
Both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medicinal products; these patients were excluded from clinical trials.